This blog is related to the various litigations related to patents w.r.t pharma industry.
Monday, December 1, 2008
MedImmune Receives FDA Complete Response Letter on Motavizumab
Nov. 28, 2008-AstraZeneca today announced that MedImmune, its wholly owned biologics business, has received a Complete Response Letter (CRL) from the U.S. FDA asking for additional information on motavizumab.
No comments:
Post a Comment